Survival following allogeneic transplant in patients with myelofibrosis
Last Updated: Friday, March 12, 2021
Data from a large multicenter retrospective study of patients with myelofibrosis treated with or without allogeneic hematopoietic cell transplantation (HCT) demonstrated long-term overall survival advantage among patients with DIPSS intermediate-1 or higher risk disease who received HCT (non-HCT vs HCT: DIPSS-Int-1: HR, 2.64, P < .0001; DIPSS-Int-2 and higher: HR, 2.55, P < .0001) but also early transplant-related mortality.
Advertisement
News & Literature Highlights